ArticleBMC infectious diseases2025
A predictive model for evaluating the risk of latent tuberculosis relapse via machine learning.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundReactivation of latent tuberculosis infection (LTBI) is a major obstacle to tuberculosis eradication. Predicting LTBI relapse is crucial for effective disease management but remains underexplored.
methodsWe analysed gene expression data from the GSE54992 dataset via differential expression analysis and weighted gene co-expression network analysis (WGCNA) to identify genes associated with LTBI relapse. A risk-predictive model was developed using three genes (ALG2, FARS2, and PGP) selected through a support vector machine with recursive feature elimination (SVM-RFE), least absolute shrinkage and selection operator (LASSO), and random forest algorithms. Model performance was assessed via the area under the receiver operating characteristic curve (AUC). Gene set enrichment analysis (GSEA) was employed to predict correlations between gene activities and immune pathways in monocytes, and gene expression was validated in infected macrophages.
resultsWe identified 279 co-differentially expressed genes between LTBI and active tuberculosis infection (ATBI) patients. A final set of three predictive genes (ALG2, FARS2, and PGP) was selected, yielding AUC values of 0.781 and 0.725 for validation. GSEA revealed that ALG2 was associated with immune response pathways, whereas FARS2 and PGP were linked to energy and lipid metabolism in LTBI. The expression levels of these three genes were correlated with the BCG load.
conclusionThis integrative model provides a robust tool for assessing LTBI reactivation risk and supports more personalized tuberculosis management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.